期刊文献+

吸入布地奈德对AECOPD患者气道促炎/抗炎介质水平的影响 被引量:4

Influence of inhaled budesonide on the levels of pro-inflammatory/anti-inflammatory mediators in the induced sputum of patients with AECOPD
下载PDF
导出
摘要 目的测定AECOPD患者雾化吸入布地奈德前后诱导痰中TNF-α和sTNF-R55、sTNF-R75水平,阐明吸入布地奈德是否影响TNF-α系统。方法检测57例AECOPD患者(吸入组28例,常规组29例)入院时和治疗第7天诱导痰中TNF-α和sTNF-R55、sTNF-R75水平及肺功能的变化。结果吸入组治疗后FEV1、FEV1%、FEV1/FVC、PaO2的改善优于常规组,其中FEV1、FEV1%的改善有显著性。吸入组诱导痰中TNF-α、sTNF-R55和sTNF-R75水平显著低于治疗前。常规组诱导痰中TNF-α、sTNF-R55和sTNF-R75水平低于治疗前,其中TNF-α和sTNF-R75的差异有显著性。治疗后吸入组诱导痰中TNF-α、sTNF-R55和sTNF-R75的水平较常规组显著降低。结论吸入布地奈德利于TNF-α、sTNFR水平降低,有助于TNF-α/sTNF-R恢复平衡,减轻气道炎症反应,改善肺功能。 Objective To elucidate the influence of budesonide on TNF-α system by detecting the levels of TNF-α,sTNF-R55 and sTNF-R75 in induced sputum of patients with AECOPD before and after the treatment.Methods 57 patients with AECOPD were randomly divided into the inhalation group(28 cases) and the routine group(29 cases).The routine group received only standard treatment while the inhalation group received budesonide.The lung function and the levels of TNF-α,sTNF-R55 and sTNF-R75 in the induced sputum were measured and analyzed before and 6 days after the treatment.Results After the treatment,the improvement of FEV1,FEV1%,FEV1/ FVC and PaO2 was more pronounced in the inhalation group than in the routine group(P〈0.05).The levels of TNF-α,sTNF-R55 and sTNF-R75 decreased obviously after the treatment in the inhalation group(P〈0.05).Conclusion The inhalation of budesonide can reduce the levels of TNF-α and sTNFR,rebalance the system of TNF-α / sTNF-R,reduce airway inflammation and improve the lung function in the treatment of AECOPD patients.
出处 《临床肺科杂志》 2013年第8期1394-1396,共3页 Journal of Clinical Pulmonary Medicine
关键词 慢性阻塞性肺疾病 诱导痰 肿瘤坏死因子Α 可溶性肿瘤坏死因子受体 布地奈德 chronic obstructive pulmonary disease induced sputum TNF-α sTNF-R budesonide
  • 相关文献

参考文献14

  • 1Churg A,Dai J,Tai H,et al. Tumor necrosis factor-alpha is central to acute cigarette smoke induced inflammation and connective tissue breakdown[ J]. Am J Respir Crit Care Med,2002,166:849 - 854. 被引量:1
  • 2Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-in- flammatory mediators in COPD: increase in soluble interleukin 1 re- ceptor 1[ during treatment of exacerbations [ J ]. Thorax, 2001,56 : 721 - 726. 被引量:1
  • 3Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of in- duced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD [ J 1. Eur Respir J, 2000, 15:109 - 115. 被引量:1
  • 4慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 5曾勉,吴健锋,谢灿茂,严英硕,陈冬梅,禤建美.慢性阻塞性肺疾病急性加重期患者规范化痰诱导安全性的初步研究[J].中华结核和呼吸杂志,2005,28(4):238-241. 被引量:45
  • 6Babu KS,Davies DE, Holgate ST. Role of tumor necrosis factor-al- pha in asthma[ J ]. Immunol Allergy Clin North Am,2004,24 : 583 - 597. 被引量:1
  • 7Aderka D, Riccardo Polosa. Stabilization of the Bioactivity of Tumor Necrosis Fact or by Its Soluble Receptors[ J] . J Exp Med, 1992, 175 : 323 -329. 被引量:1
  • 8Sikora JP, Kuzafiski W, Andrzejewska E. Soluble cytokine recep- tors sTNFR I and sTNFR U , receptor antagonist IL-I ra, and anti- inflammatory cytokines IL-IO and IL-13 in thepathogenesis of sys- temic inflammatory response syndrome in the course of burns in chil- dren[ J]. Med Sci Monit,2009,15( 1 ) :26 -31. 被引量:1
  • 9Zeng M, Wen Y, Liu LY, et al. Role of TNF-alpha, sTNF-R55 and sTNF-Iq.75 in Inflammation of Acute Exacerbations of Chronic Ob- structive Pulmonary Disease [ J ]. Respiration, 2009,78 ( 4 ) : 399 - 403. 被引量:1
  • 10Mahais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of a- cute exacerbations of chronic obstructive pulmonary disease : a ran- domized controlled trial[ J]. Am J Respir Crit Care Med, 2002, 165:698 - 703. 被引量:1

二级参考文献19

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2Pin I,Gibson PG,Kolendowicz R,et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax,1992,47:25-29. 被引量:1
  • 3Sutherland ER,Pak J,Langmack EL,et al. Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease. Respir Med,2002,96:482-486. 被引量:1
  • 4Fabbri LM,Hurd SS,GOLD Scientific Committee. Global strategy for the diagnosis,management and prevention of COPD:2003 update. Eur Respir J,2003,22:1-2. 被引量:1
  • 5Celli BR,MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J,2004,23:932-946. 被引量:1
  • 6Bach PB,Brown C,Gelfand SE,et al. Management of acute exacerbations of chronic obstructive pulmonary disease:a summary and appraisal of published evidence. Ann Intern Med,2001,134:600-620. 被引量:1
  • 7Vignola AM,Rennar SI,Hargreave FE,et al. Standardised methodology of sputum induction and processing. Future directions. Eur Respir J Suppl,2002,37:51s-55s. 被引量:1
  • 8Tsoumakidou M,Tzanakis N,Siafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir Med,2003,97:863-871. 被引量:1
  • 9Vlachos-Mayer H,Leigh R,Sharon RF,et al. Success and safety of sputum induction in the clinical setting. Eur Respir J,2000,16:997-1000. 被引量:1
  • 10Rohde G,Wiethege A,Borg I,et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation:a case-control study. Thorax,2003,58:37-42. 被引量:1

共引文献8262

同被引文献49

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部